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Dr. Barie has described a small series of pa-
tients with AIDS who underwent percutaneous 
cholecystostomy for acute cholecystitis, with good 
results and little associated morbidity. Because of 
this limited experience, he suggests that this is the 
"standard of care" at his institution. Percutaneous 
cholecystostomy has a distinct role in the manage-
ment of patients for whom the risks of operative 
intervention and anesthesia are overwhelming. 
But our institutional experience and an extensive 
review of the literature suggest that surgery is con-
traindicated in only the smallest minority of pa-
tients with AIDS-related biliary disease. We have 
demonstrated that cholecystectomy is a safe inter-
vention in this population of patients. Cholecys-
tectomy resolves the pathology by removing the 
infected organ and provides more lasting benefit. 
The expected survival after a bout with cholecys-
titis is measured in years, not weeks or months. For 
this reason, the likelihood of ultimately having to 
intervene surgically is high after a temporizing 
procedure such as cholecystostomy. 
There are other reasons to avoid cholecystostomy 
in patients with AIDS. Longterm, indwelling drains 
in patients with infectious disease may pose a biohaz-
ard, both in the hospital and in the home setting. 
Definitive cholecystectomy may also help to resolve 
infection in the remaining portion of the biliary tree. 
Our experience with a small number of patients who 
had biliary tree (including gallbladder) overgrowth 
with either cryptosporidium or cytomegalovirus sug-
gests that once the gallbladder is removed, over-
growth of the biliary tree regresses. I am concerned 
that such regression in disease may not follow drain-
age alone. 
As our understanding of HIV and AIDS has 
grown, we have been better able to discern the true 
role of surgery in the treatment of its complications. 
The most difficult distinction is in determining 
what level of therapy is "too" aggressive and what 
is not aggressive enough. In our experience, cho-
lecystectomy represents the appropriate level of 
care for patients with HIV/AIDS who have 
cholecystitis. 
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Pancreas Transplantation 
Robert]. Corry, MD, FACS, and Thomas E. Starzl, 
MD, phD, FACS, Professors of Surgery, Pittsburgh, PA 
The article entitled " ... Surgical Risk of Pancreas 
Transplantation ... " by Gruessner, Sutherland, and 
associates in the August issue emphasizes several im-
portant points about this complex procedure, which 
is still viewed as "experimental" by several health care 
funding agencies, including the Health Care Financ-
ing Administration. 
The Minnesota group, which initiated the clini-
cal procedure in 1966,1 has pioneered the evolution 
of pancreas transplantation for the past 3 decades 
under the direction of David Sutherland. The ques-
tion has always been raised whether the procedure, 
which is associated with considerable morbidity, is 
worth the potential risk. The authors have presented 
an honest appraisal of the risk factors together with 
details, statistics, and results, including the effects of 
surgical complications on graft success rates and pa-
tient survival. Of particular interest, the subgroup of 
recipients that required relaparotomy (32%) had a 
77% I-year patient survival rate in the pancreas/ 
kidney group compared with an 87% survival rate in 
the remaining 68% who did not require reoperation. 
The effect of relaparotomy on I-year graft survival 
was more devastating: 32% versus 82%. 
In our series of 123 consecutive patients who 
received cadaveric pancreas transplantation in the 
last 3 years (all but 17 having simultaneous trans-
plantation with a kidney), one died after multiple 
reoperations for septic complications. Two others 
having no relaparotomy died at 4 and 8 months of 
posttransplant lymphoma and a midbrain stroke, re-
spectively. Our graft success rate (median followup 
1-5 years) was 56% in the 41 reoperated patients 
versus 95% in the 82 patients who did not require 
relaparotomy. If nine patients with low perfusion/ 
thrombosis requiring graft removal within the first 
week were excluded from the reoperated group, the 
graft success rate was 78%. 
Although we continue to use bladder drainage in 
some recipients of pancreas-only to monitor the uri-
nary amylase level as an indicator of rejection, we 
have increasingly used enteric drainage for all pan-
creas grafts because of its lower complication rate. 2 
Dehydration and acidosis do nor occur, eliminating 
the conversion from bladder to enteric drainage, 
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Our use of tacrolimus-based immunosuppres-
sion without prophylactic antilymphoid induction 
therapy and rapid tapering of steroids has reduced 
the incidence of both viral and bacterial infections, 
while allowing good control of rejection. In recipient 
selection, it is important to avoid patients with ad-
vanced, uncorrectable coronary artery disease. In our 
opinion, donor exclusion based on an arbitrary age 
ceiling is unnecessarily restrictive. A decision to use 
an organ can be made wisely from its gross appear-
ance and texture, the adequacy of the venous efflux of 
chilled flush solution after benchwork reconstruc-
tion, and the quality of the vessels. 
Surgical complications associated with pancreas 
transplantation should not necessarily result in an 
increased mortality rate or a high incidence of graft 
loss. 
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In Reply 
Rainer W. G. Gruessner, MD, PhD, Minneapolis, MN 
We appreciate the interest and the insightful com-
ments of Drs. Corry and Starzl regarding our article 
"The Surgical Risk of Pancreas Transplantation in 
the Cyclosporine Era: An Overview," published in 
the Journal of the American College of Surgeons in Au-
gust 1997. 1 Drs. Corry and Starzl of the University of 
Pittsburgh raised the following issues, all pivotal ro 
successful pancreas transplantation: 1) immunosup-
pressive therapy, 2) management of pancreas graft 
exocrine secretions, 3) donor and recipient selection 
criteria, and 4) the impact of surgical complications 
on outcome. 
1) As stated in its tide, our article represents a 
hisroric overview of the surgical risk of pancreas 
transplantation in the cyclosporine era, covering the 
period from January 1, 1986 through July 31, 1994. 
Since mid-1994, tacrolimus has been used by many 
transplant centers (including ours) as the mainstay of 
immunosuppressive therapy after pancreas trans-
plantation. Drs. Corry and Stanl reported improved 
patient and graft outcomes in their series when ta-
crolimus was used. The superiority of tacrolimus-
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based (over cydosporine-based) immunosuppression 
has also been documented in a multicenter analysis.2 
In our historic overview, patients receiving tacroli-
mus were not included. 
Since August 1, 1994, we have used tacrolimus-
based immunosuppression for 234 pancreas trans-
plant recipients. As in the Pittsburgh experience, our 
I-year patient and graft survival rates (95% and 
78%, respectively) have been significantly higher 
with tacrolimus than with cyclosporine. A total of 51 
(22%) patients receiving tacrolimus underwent re-
laparotomy (compared with 32% in the cyclosporine 
era, as stated in our article). Similarly, only 23 recip-
ients (10%) of tacrolimus required treatment for in-
traabdominal infection (compared with 20% in the 
cyclosporine era, as stated in our article). In the ta-
crolimus era, not only has the surgical complication 
rate decreased, but the number of graft losses from 
rejection has also decreased. These improvements in 
overall outcome are largely due to tacrolimus, but 
also reflect the introduction of another new immu-
nosuppressive drug, mycophenolate mofetil; the use 
of more efficient, yet less toxic, antimicrobial agents; 
refinements of the transplant procedure itself; bener 
diagnosis of rejection because of more liberal use of 
biopsies; and better selection of donors and 
recipients. 
Drs. Corry and Starzl suggest that tacrolimus-
based immunosuppression allows avoidance of pro-
phylactic anti-T-cell induction therapy after pan-
creas transplantation. This possibility still needs to be 
studied prospectively. A multicenter study will begin 
by the end of this year that will use tacrolimus-based 
immunosuppression and will compare outcomes 
with, versus without, anti-T-cell induction therapy. 
2} The optimal technique to handle pancreas 
graft exocrine secretions has been the subject of on-
going discussion since the beginning of pancreas 
transplantation. Historically, the incidence of techni-
cal failure has been greater with enteric (versus blad-
der) drainage--one of the reasons that bladder drain-
age has become the most common technique to drain 
the exocrine secretions. In addition, bladder drainage 
allows graft exocrine function to be monitored by 
measuring pancreas enzymes secreted directly inro 
the urine. The disadvantage of bladder drainage is 
that it can cause metabolic, pancreatic, or urinary 
complications that may ultimately require takedown 
of the duodenocystostomy and conversion (0 enteric 
drainage. 
Enteric drainage will replace bladder drainage 
only if it can be shown that graft survival is equiva-
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lent, both shortterm and longterm. According to the 
latest update by the International Pancreas Trans-
plant Registry,3 the I-year graft survival rate with 
bladder drainage is 83%; with enteric drainage with 
Roux-en-Y, 80%; and with enteric drainage without 
Roux-en-Y, 77% (overall p < 0.1). The difference in 
graft survival is not significant for bladder drainage 
versus enteric drainage with Roux-en-Y or for enteric 
drainage with versus without Roux-en-Y. But the dif-
ference is significant for bladder drainage versus en-
teric drainage without Roux-en-Y. 3 These results 
have been reported only for recipients of simulta-
neous pancreas-kidney transplants, in whom the kid-
ney graft is considered a surrogate marker of rejec-
tion. Because renal markers for rejection cannot be 
used after solitary pancreas transplantation, we cur-
rently recommend against enteric drainage for soli-
tary pancreas grafts. 
3) Outcomes after pancreas transplantation are 
largely influenced by prudent selection of donors and 
recipients. In a multivariate analysis, we showed pre-
viously that the presence of pretransplant cardiac dis-
ease (myocardial infarction, bypass, angioplasty) 
placed pancreas transplant recipients at a higher risk 
of death with a functioning graft.4 This finding is in 
line with Drs. Corry and Starzl's recommendation 
not to perform transplantation in candidates with 
advanced, uncorrectable coronary artery disease. 
We have recommended against the use of donors 
> 45 years old. We agree that this arbitrary age ceil-
ing is restrictive, but it provides a guideline for 
smaller transplant centers. Repeated analyses by the 
International Pancreas Transplant Registry have 
shown significantly less favorable outcomes with do-
nors 2: 45 years 01d.3 Surgeons with experience in 
pancreas transplantation can and should weigh other 
factors (besides donor age) in deciding on a particular 
donor organ, such as its gross appearance and texture. 
In our own experience, pancreas grafts from donors 
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2: 45 years old can be transplanted successfully, but 
results are more consistently good with donors < 45 
years of age. 
4) In our experience, surgical complications con-
tinue to have a negative impact on graft outcomes 
and hospital costs,5 despite the use of tacrolimus. In 
the Pittsburgh series, graft survival was 39% lower 
for recipients who underwent a relaparotomy after 
transplantation versus those who did not. In our se-
ries, I-year graft survival in recipients of tacrolimus 
was 83% without versus 55% with a relaparotomy 
after transplantation (p < 0.0001). Pancreas trans-
plantation remains a procedure that requires metic-
ulous attention to technical detail. Any minor tech-
nical error can have catastrophic consequences. 
In conclusion, we agree with Drs. Corry and 
Starzl that tacrolimus has further improved the re-
sults of pancreas transplantation. More than 1,000 
pancreas transplant procedures are now performed 
annually in the United States. This procedure has 
become a well-established treatment option for pa-
tients with insulin-dependent type I diabetes melli-
tus. We hope that, in the near future, Medicare and 
Medicaid will join the increasing number of insur-
ance providers that cover pancreas transplants. 
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